{"id":"toludesvenlafaxine-hydrochloride-sustained-release-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Sexual dysfunction"},{"rate":null,"effect":"Sweating"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting the reuptake of both serotonin and norepinephrine, toludesvenlafaxine enhances monoaminergic neurotransmission in the central nervous system. The sustained-release formulation provides prolonged drug exposure, allowing for once-daily dosing. This mechanism is thought to restore neurochemical balance in mood disorders and anxiety conditions.","oneSentence":"Toludesvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases synaptic levels of serotonin and norepinephrine by blocking their reuptake at the presynaptic membrane.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:13:09.420Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"}]},"trialDetails":[{"nctId":"NCT05849272","phase":"PHASE4","title":"Efficacy and Safety of Toluedesvenlafaxine Hydrochloride Extended-release Tablets in Somatic Symptoms of Depression","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2023-05-12","conditions":"Somatic Symptom","enrollment":60},{"nctId":"NCT06278038","phase":"NA","title":"Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Venlafaxine Hydrochloride Sustained-release Tablets in Patients With Major Depression Disorder","status":"COMPLETED","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-02-22","conditions":"Major Depression Disorder","enrollment":84},{"nctId":"NCT06426485","phase":"PHASE4","title":"To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets","status":"NOT_YET_RECRUITING","sponsor":"Luye Pharma Group Ltd.","startDate":"2024-05-30","conditions":"Major Depressive Disorder","enrollment":736},{"nctId":"NCT06270433","phase":"NA","title":"Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder","status":"RECRUITING","sponsor":"Jiangsu Province Nanjing Brain Hospital","startDate":"2024-02-19","conditions":"Anhedonia","enrollment":80},{"nctId":"NCT05970510","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.","status":"RECRUITING","sponsor":"Luye Pharma Group Ltd.","startDate":"2023-07-12","conditions":"Generalized Anxiety Disorder","enrollment":555},{"nctId":"NCT06026917","phase":"PHASE4","title":"Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2023-09-25","conditions":"Major Depressive Disorder","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"toludesvenlafaxine hydrochloride sustained-release tablets","genericName":"toludesvenlafaxine hydrochloride sustained-release tablets","companyName":"Shanghai Mental Health Center","companyId":"shanghai-mental-health-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Toludesvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases synaptic levels of serotonin and norepinephrine by blocking their reuptake at the presynaptic membrane. Used for Major depressive disorder, Generalized anxiety disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}